TechSeeker Profile

Calando Pharmaceuticals Inc (AKA: Insert Therapeutics)
Profile last edited on: 4/4/2022

Targeted therapeutics for the development of nanoparticle drug formulations.
TS Type
Small Corp
Year Founded
Last Involved Year

Key People / Management

Location Information

225 South Lake Avenue 3rd Floor
Pasadena, CA 91101
   (626) 683-7200

Public Profile

Previously doing business as Insert Therapeutics before changing its name to Calando Pharmacueticals, the firm was anchored primarily in work coming out of Cal tech. As of October 2009, Calando has operated as a majority-owned subsidiary of Arrowhead Research Corporation. The firm went into Chapter 7 Bankruptcy in 2014 and soon after relocated and is again open for business again with a different but credentialed management team. Calando Pharmaceuticals Inc is a biopharmaceutical company focused on creating targeted therapeutics using its patented and proprietary cyclodextrin-based polymer technologies for the development of nanoparticle drug formulations. Calando’s initial emphasis has been to bring targeted siRNA and small molecule therapeutics to the clinic for oncology applications; however, the technologies are not limited to these classes of molecules and are applicable to a very broad range of therapeutic entities and diseases. The Calando technology for RNAi, called RONDEL™, overcomes the significant hurdles to efficient, systemic delivery of siRNA. Calando’s technology for siRNA therapeutics: * Allows for repeat dosing without the risk of immune reactions * Has demonstrated efficient, targeted delivery in animal models * Has overcome the extra- and intra-cellular barriers to siRNA delivery * Has been scaled-up and manufactured for clinical use. In addition to the RNAi technologies and pipeline, Calando Pharmaceuticals has a therapeutic pipeline that involves small molecule drugs.

Extent of SBIR involvement

User Avatar

Synopsis: Techseeker Business Condition

Privately Held
Stock Info
Received SBIR $$

Techseeker firm in the news

There are no news available.